FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163284774> ?p ?o ?g. }

• W3163284774 endingPage "847" @default.
• W3163284774 startingPage "836" @default.
• W3163284774 abstract "Summary Background Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. We aimed to determine the efficacy and safety of ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab) compared with ipilimumab monotherapy in patients who are resistant to anti-PD-(L)1 therapy (hereafter referred to as anti-PD-[L]1). Methods This multicentre, retrospective, cohort study, was done at 15 melanoma centres in Australia, Europe, and the USA. We included adult patients (aged ≥18 years) with metastatic melanoma (unresectable stage III and IV), who were resistant to anti-PD-(L)1 (innate or acquired resistance) and who then received either ipilimumab monotherapy or ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab), based on availability of therapies or clinical factors determined by the physician, or both. Tumour response was assessed as per standard of care (CT or PET–CT scans every 3 months). The study endpoints were objective response rate, progression-free survival, overall survival, and safety of ipilimumab compared with ipilimumab plus anti-PD-1. Findings We included 355 patients with metastatic melanoma, resistant to anti-PD-(L)1 (nivolumab, pembrolizumab, or atezolizumab), who had been treated with ipilimumab monotherapy (n=162 [46%]) or ipilimumab plus anti-PD-1 (n=193 [54%]) between Feb 1, 2011, and Feb 6, 2020. At a median follow-up of 22·1 months (IQR 9·5–30·9), the objective response rate was higher with ipilimumab plus anti-PD-1 (60 [31%] of 193 patients) than with ipilimumab monotherapy (21 [13%] of 162 patients; p Interpretation In patients who are resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 seemed to yield higher efficacy than ipilimumab with a higher objective response rate, longer progression-free, and longer overall survival, with a similar rate of grade 3–5 toxicity. Ipilimumab plus anti-PD-1 should be favoured over ipilimumab alone as a second-line immunotherapy for these patients with advanced melanoma. Funding None." @default.
• W3163284774 created "2021-05-24" @default.
• W3163284774 creator A5003153310 @default.
• W3163284774 creator A5009968141 @default.
• W3163284774 creator A5013399740 @default.
• W3163284774 creator A5017778536 @default.
• W3163284774 creator A5022520811 @default.
• W3163284774 creator A5022668182 @default.
• W3163284774 creator A5025067315 @default.
• W3163284774 creator A5025478490 @default.
• W3163284774 creator A5029398339 @default.
• W3163284774 creator A5036987287 @default.
• W3163284774 creator A5038759671 @default.
• W3163284774 creator A5040969461 @default.
• W3163284774 creator A5050031536 @default.
• W3163284774 creator A5052403208 @default.
• W3163284774 creator A5059961435 @default.
• W3163284774 creator A5064026461 @default.
• W3163284774 creator A5064923908 @default.
• W3163284774 creator A5065819179 @default.
• W3163284774 creator A5069095893 @default.
• W3163284774 creator A5069983533 @default.
• W3163284774 creator A5071144743 @default.
• W3163284774 creator A5071577704 @default.
• W3163284774 creator A5082278497 @default.
• W3163284774 creator A5083061830 @default.
• W3163284774 creator A5087156406 @default.
• W3163284774 creator A5087469853 @default.
• W3163284774 creator A5088390068 @default.
• W3163284774 creator A5090545021 @default.
• W3163284774 date "2021-06-01" @default.
• W3163284774 modified "2023-10-17" @default.
• W3163284774 title "Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study" @default.
• W3163284774 cites W2019607817 @default.
• W3163284774 cites W2128035403 @default.
• W3163284774 cites W2152897456 @default.
• W3163284774 cites W2166662937 @default.
• W3163284774 cites W2344626562 @default.
• W3163284774 cites W2529373149 @default.
• W3163284774 cites W2549612601 @default.
• W3163284774 cites W2588686192 @default.
• W3163284774 cites W2603690292 @default.
• W3163284774 cites W2752227448 @default.
• W3163284774 cites W2753432434 @default.
• W3163284774 cites W2754454631 @default.
• W3163284774 cites W2794627893 @default.
• W3163284774 cites W2797309423 @default.
• W3163284774 cites W2915708315 @default.
• W3163284774 cites W2947765148 @default.
• W3163284774 cites W2963476376 @default.
• W3163284774 cites W2966816506 @default.
• W3163284774 cites W3005546631 @default.
• W3163284774 cites W3021358555 @default.
• W3163284774 cites W3024460671 @default.
• W3163284774 cites W3043703771 @default.
• W3163284774 cites W3082455108 @default.
• W3163284774 cites W3087697977 @default.
• W3163284774 doi "https://doi.org/10.1016/s1470-2045(21)00097-8" @default.
• W3163284774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33989557" @default.
• W3163284774 hasPublicationYear "2021" @default.
• W3163284774 type Work @default.
• W3163284774 sameAs 3163284774 @default.
• W3163284774 citedByCount "88" @default.
• W3163284774 countsByYear W31632847742021 @default.
• W3163284774 countsByYear W31632847742022 @default.
• W3163284774 countsByYear W31632847742023 @default.
• W3163284774 crossrefType "journal-article" @default.
• W3163284774 hasAuthorship W3163284774A5003153310 @default.
• W3163284774 hasAuthorship W3163284774A5009968141 @default.
• W3163284774 hasAuthorship W3163284774A5013399740 @default.
• W3163284774 hasAuthorship W3163284774A5017778536 @default.
• W3163284774 hasAuthorship W3163284774A5022520811 @default.
• W3163284774 hasAuthorship W3163284774A5022668182 @default.
• W3163284774 hasAuthorship W3163284774A5025067315 @default.
• W3163284774 hasAuthorship W3163284774A5025478490 @default.
• W3163284774 hasAuthorship W3163284774A5029398339 @default.
• W3163284774 hasAuthorship W3163284774A5036987287 @default.
• W3163284774 hasAuthorship W3163284774A5038759671 @default.
• W3163284774 hasAuthorship W3163284774A5040969461 @default.
• W3163284774 hasAuthorship W3163284774A5050031536 @default.
• W3163284774 hasAuthorship W3163284774A5052403208 @default.
• W3163284774 hasAuthorship W3163284774A5059961435 @default.
• W3163284774 hasAuthorship W3163284774A5064026461 @default.
• W3163284774 hasAuthorship W3163284774A5064923908 @default.
• W3163284774 hasAuthorship W3163284774A5065819179 @default.
• W3163284774 hasAuthorship W3163284774A5069095893 @default.
• W3163284774 hasAuthorship W3163284774A5069983533 @default.
• W3163284774 hasAuthorship W3163284774A5071144743 @default.
• W3163284774 hasAuthorship W3163284774A5071577704 @default.
• W3163284774 hasAuthorship W3163284774A5082278497 @default.
• W3163284774 hasAuthorship W3163284774A5083061830 @default.
• W3163284774 hasAuthorship W3163284774A5087156406 @default.
• W3163284774 hasAuthorship W3163284774A5087469853 @default.
• W3163284774 hasAuthorship W3163284774A5088390068 @default.
• W3163284774 hasAuthorship W3163284774A5090545021 @default.
• W3163284774 hasConcept C121608353 @default.
• W3163284774 hasConcept C126322002 @default.
• W3163284774 hasConcept C143998085 @default.

• next